SCHEMBL1724926

SCHEMBL1724926

NC(=O)c1cccnc1C(=O)NCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.59
KMT2A Q03164 4/20 0.58
MAPK8 P45983 1/20 0.56
ATM Q13315 1/20 0.56
RPS6KB1 P23443 1/20 0.55
EGLN1 Q9GZT9 1/20 0.53
GAA P10253 2/20 0.51
ALDH1A1 P00352 1/20 0.51
ADORA2A P29274 1/20 0.51
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 2/20 0.49
MEN1 O00255 1/20 0.49
KDM4E B2RXH2 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.49
HPGDS O60760 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715714 0.88 KMT2A (0.64) NSD2KMT2AMAPK8ATMEGLN1
SCHEMBL3556910 0.88 KMT2A (0.64) NSD2KMT2AMAPK8ATMEGLN1
SCHEMBL31026208 0.82 KMT2A (0.61) NSD2KMT2AMAPK8ATMEGLN1
SCHEMBL7138975 0.82 KMT2A (0.61) NSD2KMT2AMAPK8ATMEGLN1
SCHEMBL8154709 0.82 KMT2A (0.80) NSD2KMT2AMAPK8ATMEGLN1
SCHEMBL31026221 0.81 EGLN2 (0.68) NSD2KMT2AMAPK8ATMRPS6KB1
SCHEMBL7452205 0.81 KDM4E (0.52) KMT2AGAAALDH1A1HPGDL3MBTL1
SCHEMBL31026200 0.80 HTT (0.56) NSD2KMT2AMAPK8ATMLMNA
SCHEMBL3958929 0.79 KMT2A (0.61) NSD2KMT2AMAPK8ATMEGLN1
SCHEMBL15402857 0.79 KDM4E (0.48) KMT2AALDH1A1HPGDL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109701574-B Preparation of nitrogen-modified carbon-supported noble metal hydrogenation catalyst and application of nitrogen-modified carbon-supported noble metal hydrogenation catalyst in hydrogenation reaction of pyridine ring compounds 浙江工业大学 2022-04-19 CN claimed
CN-116987075-A Process for preparing pyridine dicarboximide compound 浙江新和成股份有限公司 2023-11-03 CN disclosed
CN-109701574-B Preparation of nitrogen-modified carbon-supported noble metal hydrogenation catalyst and application of nitrogen-modified carbon-supported noble metal hydrogenation catalyst in hydrogenation reaction of pyridine ring compounds 浙江工业大学 2022-04-19 CN disclosed
EP-2403831-B1 SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLOÝ3,4-b¨PYRIDINE ITALIANA SINT SPA (IT) 2015-05-20 EP disclosed
US-8680276-B2 Synthesis of (4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridine F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) 2014-03-25 US disclosed
CN-103613592-A Synthesis method of aromatic ring or aromatic heterocyclic ring-fused amide DALIAN JOIN KING BIO CHEMICAL TECHNOLOGY CO LTD 2014-03-05 CN disclosed
EP-2403831-A1 SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLOÝ3,4-b¨PYRIDINE F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) 2012-01-11 EP disclosed
US-20110137036-A1 SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) 2011-06-09 US disclosed
WO-2010100215-A1 SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137036-A1 SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE PDXK, OXA1L, PDK4 NSD2 4851/4885KMT2A 4545/4885MAPK8 2963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.